- Home
- COCH vs RLYB Comparison
COCH vs RLYB Comparison
Compare COCH & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COCH | RLYB |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 28.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | COCH | RLYB |
|---|---|---|
| Price | $0.76 | $4.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | ★ 171.5K | 23.8K |
| Earning Date | 03-30-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $208,000.00 | ★ $674,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.71 |
| 52 Week Low | $0.38 | $1.76 |
| 52 Week High | $1.91 | $6.99 |
Technical Indicators
Market Signals| Indicator | COCH | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 94.27 |
| Support Level | $0.43 | $0.56 |
| Resistance Level | $0.68 | $5.00 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | -0.00 | 0.50 |
| Stochastic Oscillator | 81.46 | 87.74 |
Price Performance
Historical ComparisonAbout COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.